Definitive Contract HHSN272201500009C

This is a $30,704,925.57 cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services, to Achaogen, Inc., a for-profit organization. The contract was awarded on September 1, 2008, with a period of performance through August 27, 2016, and was not set aside for any specific business type. The contract was awarded under a Broad Agency Announcement (BAA) solicitation, BAA...

This is a $4,590,862.00 cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Sorrento Therapeutics, Inc., a small disadvantaged business. The contract is for the "DEVELOPMENT OF IN VITRO FOR BIODEFENSE, ANTIMICROBIAL RESISTANT (AMR) INFECTIONS AND EMERGING INFECTIOUS DISEASES", which was a Broad Agency Announcement (BAA) research area. The contract has a period of performance through May 2, 2025...

This is a $575,850.00 fixed-price delivery order awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the In Vitro Antimicrobial Assessments 2011-2018 indefinite-delivery, indefinite-quantity (IDIQ) contract. The contract was awarded to Access To Advanced Health Institute (AAHI), a nonprofit biotech research institute located in Seattle, Washington. The contract is for unspecified "OTHER FUNCTIONS" and does not have a set-aside designation. As a prime...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a definitive contract to Revagenix Inc. valued at approximately $27.8 million on September 22, 2022, for the development of a novel LPXC inhibitor with pan-resistant Pseudomonas and Burkholderia activity. The contract, which will be performed in San Mateo, California, is structured as a cost-plus-fixed-fee arrangement with an ultimate completion date of April 25, 2028. This award originated from a Broad Agency Announcement...

This is a $18,576,013.05 cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to the Access To Advanced Health Institute (AAHI), a non-profit biotech research institute located in Seattle, Washington. The contract is for the development of vaccine candidates for biodefense, antimicrobial resistant infections, and emerging infectious diseases, under NIAID's Broad Agency Announcement (BAA) Research Area 001. AAHI...

The National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, awarded a $15,505,000.31 definitive cost-no-fee contract to Entasis Therapeutics Inc., a subsidiary of Innoviva, Inc., to identify and develop a non-beta-lactam penicillin-binding protein (PBP) inhibitor with broad-spectrum activity against multidrug-resistant Gram-negative ESKAPE pathogens. This work directly responds to a NIAID solicitation for proposals addressing...

This is a $7,621,277 cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Microbiotix, Inc., a clinical-stage biopharmaceutical company in Worcester, Massachusetts. The contract is to develop phenoxyacetamide T3SS inhibitors as adjunctive agents to antibacterial therapy for treating multidrug-resistant Pseudomonas aeruginosa infections. This work was originally solicited through a Broad Agency Announcement seeking proposals to develop...

The U.S. Department of Health and Human Services' National Institute of Allergy and Infectious Diseases (NIAID) has awarded a $3,318,955.00 cost-plus-fixed-fee definitive contract to Locus Biosciences Inc., a clinical-stage biopharmaceutical company, to advance a novel therapeutic to a first-in-human clinical study. This contract does not have a set-aside designation. The awardee, Locus Biosciences Inc., is developing antibacterial therapies using engineered bacteriophages, or viruses that can...

This is a $27,032,719.27 cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Spero Therapeutics, Inc. to advance the clinical and non-clinical development of an antibiotic candidate. The contract is not set aside. The contract originated from a NIAID Broad Agency Announcement (BAA) soliciting proposals for the advanced development of vaccine candidates, therapeutic products, and diagnostics to address biodefense, antimicrobial...

<p>This is a $11,286,393.00 cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Aligos Therapeutics Inc. to conduct clinical development of a compound for the treatment of COVID-19. The contract has an ultimate completion date of December 31, 2026 and does not have a set-aside designation. The award supports NIAID's efforts to develop COVID-19 treatments.</p>